PRODIGE 90 - (FFCD 2204) - PREDIR-NEOREC Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients: a Randomized Phase II Trial Phase II Randomized Study Non-comparative - Multicenter
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs Dostarlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jan 2025 New trial record